WO2003013578A8 - Omoxin agonists and antagonists for use in the treatment of metabolic disorders - Google Patents

Omoxin agonists and antagonists for use in the treatment of metabolic disorders

Info

Publication number
WO2003013578A8
WO2003013578A8 PCT/IB2002/003344 IB0203344W WO03013578A8 WO 2003013578 A8 WO2003013578 A8 WO 2003013578A8 IB 0203344 W IB0203344 W IB 0203344W WO 03013578 A8 WO03013578 A8 WO 03013578A8
Authority
WO
WIPO (PCT)
Prior art keywords
omoxin
agonists
antagonists
activity
treatment
Prior art date
Application number
PCT/IB2002/003344
Other languages
French (fr)
Other versions
WO2003013578A1 (en
Inventor
John Lucas
Deno Dialynas
Kristen Briggs
Original Assignee
Genset Sa
John Lucas
Deno Dialynas
Kristen Briggs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, John Lucas, Deno Dialynas, Kristen Briggs filed Critical Genset Sa
Priority to AU2002328173A priority Critical patent/AU2002328173A1/en
Publication of WO2003013578A1 publication Critical patent/WO2003013578A1/en
Publication of WO2003013578A8 publication Critical patent/WO2003013578A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of OMOXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
PCT/IB2002/003344 2001-08-07 2002-08-05 Omoxin agonists and antagonists for use in the treatment of metabolic disorders WO2003013578A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002328173A AU2002328173A1 (en) 2001-08-07 2002-08-05 Omoxin agonists and antagonists for use in the treatment of metabolic disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31073101P 2001-08-07 2001-08-07
US31078401P 2001-08-07 2001-08-07
US60/310,731 2001-08-07
US60/310,784 2001-08-07
US33394601P 2001-11-19 2001-11-19
US60/333,946 2001-11-19

Publications (2)

Publication Number Publication Date
WO2003013578A1 WO2003013578A1 (en) 2003-02-20
WO2003013578A8 true WO2003013578A8 (en) 2003-05-01

Family

ID=27405471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003344 WO2003013578A1 (en) 2001-08-07 2002-08-05 Omoxin agonists and antagonists for use in the treatment of metabolic disorders

Country Status (2)

Country Link
AU (1) AU2002328173A1 (en)
WO (1) WO2003013578A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360032T1 (en) 1997-09-12 2007-05-15 Biogen Idec Inc CYSTEIN-RICH RECEPTOR TRAIN
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
US7769765B2 (en) 2006-07-25 2010-08-03 Lockheed Martin Corporation Method and system for sorting mail

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DK1033134T3 (en) * 1997-10-29 2007-07-16 Otsuka Pharma Co Ltd Compositions that inhibit smooth muscle proliferation and method for diagnosing arteriosclerosis
EP1085897A4 (en) * 1998-05-21 2003-03-12 Smithkline Beecham Corp Acrp30r1l, a homolog of acrp30 (30 kd adipocyte complement-related protein)
AU5129800A (en) * 1999-05-11 2000-11-21 Incyte Genomics, Inc. Extracellular matrix and adhesion-associated proteins
EP1185645A1 (en) * 1999-05-27 2002-03-13 ZymoGenetics, Inc. Adipocyte complement related protein homolog zacrp7
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
WO2001051645A1 (en) * 2000-01-14 2001-07-19 Genset Obg3 globular head and uses thereof for decreasing body mass

Also Published As

Publication number Publication date
AU2002328173A1 (en) 2003-02-24
WO2003013578A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
HUS1600042I1 (en) Therapeutic use of anti-CS1 antibodies
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
WO2004047760A3 (en) Novel chemical compounds
WO2004110376A3 (en) Ccr-2 antagonists for treatment of neuropathic pain
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
BR0315598A (en) Neutralizing antibodies to gdf-8 and their uses
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
WO2005030240A3 (en) Vege-cor vege-d materials and methods for stimulation of neural stem cells
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
PL378026A1 (en) Treatment of diseases with alpha-7 nach receptor full agonists
AU2003299378A1 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2001092330A3 (en) Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
WO2003013578A8 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
WO2003013585A8 (en) Mifaxin agonists and antagonists for use in the treatment of metabolic
WO2003013604A3 (en) Migenix agonists and antagonists for use in the treatment of metabolic disorders
WO2003050281A3 (en) Fragments of the human zn-alpha2-glycolprotein and their use in methods of treatment of obesity
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2007067516A3 (en) Multiple myeloma
WO2003095485A3 (en) Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
WO2004053107A3 (en) Methods for treating diabetes
WO2004076414A3 (en) Novel compounds
WO2003030936A1 (en) Remedies for life style-related diseases or cibophobia and method of screening the same
ATE405323T1 (en) GSSP4 POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP